Moderna’s ($MRNA) addition to the Nasdaq-100 is more than an index headline: it may create a fresh stream of passive-fund attention and bring the biotechnology group back onto retail traders’ screens. That does not make smaller names such as Sellas Life Sciences ($SLS) and ImmunityBio ($IBRX) equivalent investments, but it can create a common conversation around biotech catalysts.

The distinction matters. $MRNA’s Nasdaq-100 inclusion is an index-related development, while the retail interest surrounding $SLS and $IBRX is tied to comparisons, themes, and identifiable company-specific catalysts. Traders looking beyond the newly included index constituent may be rotating attention toward smaller biotech stocks, but the underlying drivers are different.

Why Nasdaq-100 inclusion matters

Index inclusion can increase visibility because funds designed to track an index may need to add exposure to a newly included company. That potential passive-fund demand can place the stock in front of a broader pool of market participants, including institutional investors and retail traders monitoring index changes.

For $MRNA, the Nasdaq-100 addition supplies a clearly defined reason for increased market attention. The key point is not an unsupported price target or performance claim; the source context identifies the inclusion itself as the catalyst. Index membership may also encourage more discussion among traders, particularly when the company is already associated with a high-profile biotechnology sector.

That attention can spill into adjacent names. As detailed in the Stocktwits market coverage, retail traders are linking the $MRNA development with interest in $SLS and $IBRX. The comparison is best understood as a trading-attention dynamic rather than evidence that the companies share the same business profile, valuation, or risk characteristics.

IBRX has a defined regulatory calendar

Among the smaller biotechnology names, $IBRX has a specific catalyst on the calendar. ImmunityBio’s Anktiva is approved or authorized in 34 countries, according to the assignment context. That international authorization footprint gives traders a concrete data point to track as they assess the company’s regulatory narrative.

The more immediate U.S. catalyst is an expected Food and Drug Administration decision by Jan. 6, 2027, on a bladder-cancer label expansion for Anktiva. A dated regulatory decision can focus market attention because it provides a defined event window rather than an open-ended pipeline story.

That event should not be conflated with $MRNA’s Nasdaq-100 inclusion. The two developments may attract attention for different reasons: one involves index mechanics and potential passive-fund activity, while the other centers on a possible U.S. label expansion. For traders, separating those catalysts is essential when comparing companies within the same broad biotechnology conversation.

SLS belongs in a separate bucket

Sellas Life Sciences ($SLS) is part of the retail-trader comparison identified in the source, but the available assignment does not provide a specific regulatory date or other quantified catalyst for the company. That limitation is important. Interest in $SLS may reflect sector rotation or retail momentum around biotechnology, yet the supplied facts do not support assigning it the same catalyst profile as $MRNA or $IBRX.

The cleanest framework is therefore a three-part watchlist: $MRNA for index-related visibility, $IBRX for Anktiva’s 34-country authorization footprint and the Jan. 6, 2027, FDA decision, and $SLS for retail attention without a stated dated catalyst in the available source context. The names may appear together in trader discussions, but the reasons for monitoring them remain distinct.

Bottom line

Nasdaq-100 inclusion may give $MRNA an attention advantage through passive-fund mechanics and broader index visibility. That attention can encourage retail traders to examine smaller biotechnology names, including $SLS and $IBRX. Still, the data points are not interchangeable: $IBRX has a specified FDA decision date and an Anktiva authorization presence in 34 countries, while the supplied material identifies no comparable dated catalyst for $SLS.